The CMI has not issued any CMI reports since CMIR 23 (2009)

All subsequent work has been published via CMI Working Papers

Full CMI outputs, such as working papers and tables, issued after 1 March 2013 are only available to organisations that subscribe to the CMI

CMI Report 23 (2009) Graduations of the 1999-2002 life office mortality experiences: the 00 series tables
Erratum (added 5 May 2011): Formula (1) on page 22 of CMI Report 23 is incorrect. This erratum gives the corrected formula.
CMI Report 22 (2005) Sickness experience 1999-2002 for individual income protection policies
CMI Report 21 (2004) The mortality of holders of permanent (whole life and endowment) policies of assurance 1999-2002; The mortality of holders of temporary assurances issued in the United Kingdom, 1999-2002; The mortality of immediate annuitants, holders of retirement annuity policies, and holders of personal pension plans 1999-2002; The mortality of pensioners in insured group pension schemes 1999-2002; The mortality of smokers and non-smokers 1999-2002
CMI Report 20 (2001) The mortality in 1987-90 and 1991-94 of lives assured under permanent (whole life and endowment) assurances, according to cause of death; Mini-graduations of the mortality experience of smokers and non-smokers for assured lives; The mortality of impaired assured lives, 1987-98; A report on a pilot investigation into the mortality experience of pensioners of self-administered pension schemes; Inter-office comparisons; Sickness experience 1995-98 for individual income protection policies; Sickness experience 1995-98 for group income protection policies
CMI Report 19 (2000) The mortality of holders of permanent (whole life and endowment) policies of assurance 1995-98; The mortality of holders of temporary assurances issued in the United Kingdom 1995-98; The mortality of immediate annuitants, holders of retirement annuity policies and holders of personal pension plans 1995-98; The mortality of pensioners in insured group pension schemes 1995-98; The mortality of smokers and non-smokers 1995-98; Tables of mortality for pensioners combined based on the 1991-94 experience; Extension to young ages of the "92" series tables for assured lives
CMI Report 18 (2000) Sickness experience 1991-94 for individual PHI policies; Sickness termination experience 1991-94 for group PHI policies; An analysis of the PHI experience of individual companies in the United Kingdom I: claim inception rates; An analysis of the PHI experience of individual companies in the United Kingdom II: claim termination rates
CMI Report 17 (1999) Standard tables of mortality based on the 1991-94 experiences; The distribution of policies per life assured
CMI Report 16 (1998) The mortality of holders of permanent (whole life and endowment) policies of assurance 1991-94; The mortality of holders of temporary assurances issued in the United Kingdom, 1991-94; The mortality of immediate annuitants, holders of retirement annuity policies, and holders of personal pension plans 1991-94; The mortality of pensioners in insured group pension schemes 1991-94; The mortality of smokers and non-smokers 1991-94; The mortality of impaired assured lives, 1983-94; Proposed new tables for life office pensioners, normal, male and female, based on the 1991-94 experiences; Sickness experience 1987-90 for group PHI policies
CMI Report 15 (1996) Claim inception rates under PHI policies, individual 1975-90 and group 1975-86; Recovery and mortality rates of those claiming under PHI policies, individual 1975-90 and group 1975-86; Sickness experience 1983-86 for individual PHI policies; Sickness experience 1979-82 and 1983-86 for group PHI policies
CMI Report 14 (1995) The mortality of assured lives. pensioners and annuitants, 1987-90; The mortality of smokers and non-smokers, 1988-90; Mini-graduations of the mortality experience of assured lives, pensioners and annuitants, 1987-90; The mortality of impaired assured lives, 1983-90; The mortality of impaired lives 1987-90 according to cause of death; The mortality of retirement annuitants under approved pension; Arrangements in the Republic of Ireland. 1986-91; Sensitivity analysis in a multiple state model for permanent health insurance
CMI Report 13 (1993) The mortality of assured lives, pensioners and annuitants, 1983-86: update; Mortality in 1983-86 according to cause of death; Mortality tables based on the combined pensioners experience.1979-82; Mini-graduations of the mortality experiences of assured lives, pensioners and annuitants, 1983-86; The mortality of smokers and non-smokers, 1988-89; Inter-office comparisons; Calculation of continuation tables and allowance for non-recorded claims based on the PHI experience 1975-78
CMI Report 12 (1991) The analysis of permanent health insurance data
CMI Report 11 (1991) The mortality of assured lives, pensioners and annuitants 1983-86; The mortality of pensioners and annuitants 1979-84 according to cause of death; The mortality of impaired lives 1983-86; The mortality of impaired lives 1983-86 according to cause of death; Sickness experience 1979-82 for individual PHI policies
CMI Report 10 (1990) Standard tables of mortality based on the 1979-82 experiences
CMI Report 9 (1988) The graduation of the 1979-82 mortality experiences; Mortality in 1979-82 according to cause of death
CMI Report 8 (1986) Mortality of assured lives, pensioners and annuitants 1979-82; Impaired assured lives investigation; The distribution of policies per life assured; The CMI Bureau: history of computerisation and development of services; Cause of disability: individual PHI policies 1975-78; Sickness experience 1975-78 for group PHI policies
CMI Report 7 (1984) Sickness experience 1975-78 for individual PHI policies
CMI Report 6 (1983) Graduation of the mortality experience of female assured lives 1975-78; History and development; Abridged list of diseases; On a possible graduation of the Irish assured lives mortality experience; Notes on duplicates among linked policies
CMI Report 5 (1981) Mortality of assured lives 1975-78; Mortality of immediate annuitants 1975-78; Mortality of pensioners under life office pension schemes 1975-78; Mortality during 1975-78 of purchasers of retirement annuities under the provisions of the Finance Act, 1956; Mortality of assured lives 1975-78, according to cause of death; a(55) tables: q(x) at high ages; Sickness experience 1973-76 for group policies
CMI Report 4 (1979) Sickness experience 1972-75 for individual policies
CMI Report 3 (1977) Proposed standard tables for life office pensioners and annuitants; Mortality of assured lives 1971-74; Mortality of immediate annuitants 1971-74; Mortality of pensioners under life office pension schemes 1971-74; Mortality during 1971-74 of purchasers of retirement annuities under the provisions of the Finance Act, 1956; Mortality of assured lives 1971-74, according to cause of death; Investigation of sickness statistics - individual policies 1974 and 1975
CMI Report 2 (1976) Investigation of sickness statistics - individual policies 1972 and 1973; The graduation of pensioners and of annuitants mortality experience 1967-70
CMI Report 1 (1973) History and development; Mortality of assured lives 1967-70; Mortality of immediate annuitants 1967-70; Mortality of pensioners under life office pension schemes 1967-70; Mortality experienced during the period 1967-70 by purchasers of retirement annuities under the provisions of the Finance Act, 1956; Mortality of assured lives 1967-70, according to cause of death

Contact Details

If you have any questions about the CMI please email

info@cmilimited.co.uk

Filter or search events

Start date
E.g., 15/07/2020
End date
E.g., 15/07/2020

Events calendar

  • Current Issues in Life Assurance (CILA) Webinar series

    Webinar Series
    15 July 2020 - 3 August 2020

    Spaces available

    CILA is one of the pre-eminent events in the annual 'Life' calendar. Due to COVID-19 we are running the programme as a series of webinars covering topics aimed at practicing life actuaries from life offices, consulting firms and other employers of actuaries and those who work in or advise on, the life assurance market in the UK and Europe.

  • Spaces available

    Current Issues in Life Assurance - For annuity writers, a key challenge is the need to fund capital-consumptive new business strain (NBS) as a consequence of writing the business intended to fund future distributions. Reinsurance, investment strategy and capital provision all have roles to play which we will investigate in this webinar

  • Spaces available

    Current Issues in Life Assurance – Mortality in 2020 is now dominated by one thing, although – in our future-focused world – the pandemic is just one of many mortality considerations.  In this session, three well-regarded mortality/longevity specialists provide an overview of implications and impacts of COVID-19, recent and imminent CMI developments and more 'future focused' work in the MRSC

  • Spaces available

    Because of Covid-19, forecasters predict a severe recession in 2020, followed by a V or U-shaped recovery. This impacts both individuals and companies. However, compared to previous recessions, the impact on banks of higher credit losses should be mitigated to some extent by government actions. 

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series

    This session will provide an overview of the Population Health Management Working Party's research including defining impactability and impactability modelling, discussing some examples of specific modelling approaches, considering the practical challenges across the NHS as well as wider public perception and ethical issues.

  • Spaces available

    Many actuaries consider career opportunities in the Finance and Investment practice area after having started off in more traditional actuarial roles such as valuations, capital management or pricing. This session is aimed at helping actuaries to better understand roles in Finance and Investment and how they can fine tune their skills to pursue such careers.

  • Mortality and Longevity Webinar Series 2020

    Webinar Series
    22 July 2020 - 10 August 2020

    Spaces available

    Due to COVID-19, we are running this programme via a series of webinars commencing 22nd July.

    This webinar series will provide topical and practical updates and discussion on the latest thinking and innovations in mortality and longevity, and is designed to be very accessible to a broad range of experience.

     

  • Spaces available

    Insurers are making increasing use of medical research to help with assumption, models and underwriting. Experienced mortality/ longevity specialists discuss the issues in the interpretation of  medical research papers, using a range of case studies. The case studies will include COVID-19 points of current importance. Many of the concepts discussed (data bias, inference of causation) are also applicable to equivalent questions in 'big data' and advanced analytics.

  • Spaces available

    Members of the Mortality Working Group of the IAA have analysed changes in mortality for about 30 causes of death  and will discuss how causes of death are classified, and the problems of long-term data, appropriate metrics, including "years of life lost" (YLL), causes of death - a "measure of cohortness", the changes in dominant causes of death at older ages, and how can these types of studies enhance mortality forecasting.

  • Spaces available

    Predictive risk assessment and risk stratification models based on postcode-level consumer classification are widely used for life insurance underwriting. However, these are socio-economic models not directly related to health information. Similar to precision medicine, precision life insurance should aim to tailor policy pricing/reserving to the individual health characteristics of each client.

  • Spaces available

    This discussion, the fourth in the Extreme Mortality Events webinar series, will look at what poor model selection and calibration could look like – using inappropriate historical data; using incorrect 2020 mortality data; and inappropriate stochastic model recalibration (or lack thereof). Presented by Chair of the Life Board of the Institute and Faculty of Actuaries, Colin Dutkiewicz. 

  • Spaces available

    This webinar has been re-scheduled from its original date of the 1st July. Although ESG has many buyers across the asset allocation community, from pension funds to sovereign wealth funds, it still hasn’t found its place within the core asset management strategy desks where the money is actually invested. The problem as well as the opportunity is Fixed Income. Plenty of strategies exist for incorporating ESG within Equities, from screening, integration to a combination. ESG has picked up relatively quickly within Equities with rating,indices created using ESG factors. This talk will discuss how we price a quantifiable ESG credit risk premium and make it alpha worthy in a strategy. 

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series

    With the rising prevalence of dementia, how can we manage this risk effectively and can insurance do more? Matt Singleton, Ageing Lead at Swiss Re, will cover these topics and demonstrate how insurance could help people address their concerns.

  • Spaces available

    Current Issues in Life Assurance – Join us for an exploration session on the use of data science in insurance companies today including how insurers are making sense of and using new data sources and technologies, exploration of practical applications of data science within actuarial work, benefits of data-driven decisions to solve business problems using the power of data and technology, and the role that actuaries can play to harness the benefits of data science.

     

  • Spaces available

    Current Issues in Life Assurance

    This talk will look at a range of such techniques (e.g. mass lapse risk transfer, contract boundaries, risk margin relief, non-standard longevity risk transfer) that have been applied or considered by UK and EU insurers, and the pros and cons of each.

     

  • Spaces available

    Current Issues in Life Assurance.

    The International Association of Insurance Supervisors announced on 14 November 2019 the adoption of v2.0 of the global Insurance Capital Standard (ICS) which will undergo confidential reporting for 5 years starting from 2020. This session will include specific experiences from Legal and General (L&G) as well as global industry perspectives from EY.

  • Spaces available

    Current Issues in Life Assurance

    This session will cover the PRA supervisory statement on financial impacts related to climate change, industry insights into PRA climate risk business plans, examples climate risk strategy setting out key workstreams and activity steps for successful execution, an overview of a climate risk strategy execution timeline and the future.     

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series. Using new and unique research and data from the UK, US, Sweden and China, this presentation investigates how consumers use the internet through their insurance journey and analyzes the role culture and generation plays in their online behaviour. We use this research to show the online landscape for insurance sales in the UK and suggest ways to shape new products and effectively engage with the consumer who is buying them.

  • Spaces available

    Chief Medical Officer (CMO) for Gen Re Life/Health Research and Development, Dr John O'Brien, will discuss the impacts of Gene Modification for life/health insurance. 

  • Spaces available

    As an industry, it has been important to be able to look to the future to identify the next quantifiable risk. In this session, I will explore some of the less tangible, but none-the-less concerning risks to future health, such as the health risks associated with exposure to pesticides, ingestion of plastic in the food chain, and the hazards of indoor air pollution through exposure to volatile organic compounds.

  • Spaces available

    The working party will help the industry to update and enhance how potential risk from diabetes and excess mortality is considered, including the need to understand the underwriting implications as treatments improve, and potentially to develop new products that are tailored to those with diabetes.

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series. Modelling the structure and trends of cancer morbidity risk is important for pricing and reserving in related health insurance fields such as critical illness insurance and care provision. We model the dynamics of cancer incidence over time in different regions in England, using 1981-2016 ONS data. The modelling allows estimation of cancer rates at various age, year, gender and region levels, following a Bayesian setting to account for statistical uncertainty. Our analysis indicates significant regional variation in cancer incidence rates. 

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series. In this talk we will outline the steps Aviva took in pulling together our first large-scale disclosures on the exposure of our business to climate change published in March 2019; in line with the recommendations of the Taskforce on Climate-related Financial Disclosures. After touching on why insurers have such an important role in climate change, we'll cover a brief “how-to” guide for those who have not yet embarked on thinking about these topics before giving a case study of how the learnings from a TCFD disclosure exercise can be applied to investment portfolios.

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series. 

    The insurance industry currently underwrites customers with diabetes based on a range of factors, medical expertise and various medical studies. The work undertaken by the Diabetes Working Party would help the industry to approach this using current research findings to update and enhance how potential risk from diabetes is considered. This includes the need to understand the underwriting implications as treatments improve, and potentially to develop new products that are tailored to those with diabetes. This webinar will present our latest findings in the management of this important chronic condition which will include research in collaboration with the ARC.